Rose McNulty

Magnetic resonance imaging (MRI) is often used in the diagnosis and management of prostate cancer, but the method frequently underestimates tumor size, a study in the Journal of Urology shows.

Anthony Fauci gave his insight on the coronavirus disease 2019 (COVID-19) for immunocompromised populations at ASH 2020, and leading organizations released fact sheets and recommendations.

Certain elderly women with ovarian cancer might benefit from aggressive treatment methods, a study recently published in Annals of Surgical Oncology found.

Luis Carrascosa, MD, a radiation oncologist at the Florida Cancer Specialists Ocala Cancer Center, discusses new and upcoming trends in radiation therapy for prostate cancer.

Florida Cancer Specialists has integrated SpaceOAR Hydrogel into its armamentarium as a pre-treatment for radiation therapy in prostate cancer patients.

Patients with both lung cancer and autoimmune disease have no significant difference in survival than patients with lung cancer alone, according to recent research from Northwestern University.

The 2021 American Cancer Society annual Cancer Statistics report found that the overall rate of cancer mortality continuously declined from 1991 to 2018 but also highlighted racial and geographic disparities.

Our 5 most-read oncology stories and most-watched videos this year highlighted cancer care policy, diversity, and the growing practice of remote cancer care.

Robert Baird, RN, MSA, president of the National Cancer Treatment Alliance, discusses ways that employers of all sizes can pursue direct contracting with health care providers.

This year’s top 5 most-read stories in lung cancer were overrun by non–small cell lung cancer drug trial results and FDA action.

Bradley Monk, MD, FACOG, FACS, a professor at the University of Arizona, chronicles the regulatory changes in PARP inhibitors as they gain more indications in ovarian cancer.

The top 5 most-read news stories for Evidence-Based Oncology™ (EBO), a publication of The American Journal of Managed Care®, ranged from drug approvals to policy challenges and targeted therapies.

Neeraj Agarwal, MD, University of Utah Huntsman Cancer Institute, shares his experience regarding the prostate cancer patients who could potentially benefit from PARP inhibition.

Robert Baird, RN, MSA, president of the National Cancer Treatment Alliance, discusses potential issues employers can avoid by direct contracting with providers.

FDA fact sheets on coronavirus disease 2019 (COVID-19) vaccines provide guidelines for special patient populations, including the immunocompromised.

The Community Oncology Alliance's request includes declarations from community oncology practices detailing the anticipated ramifications should the Most Favored Nation rule become operative.

A new study validates the application of duplex sequencing in detecting mutations caused by chemical carcinogens.

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, professor at the University of Arizona and Creighton University in Phoenix, discusses the reimbursement of PARP inhibitors in ovarian cancer.

NSCLC patients who developed immune-related adverse events during immunotherapy showed longer overall survival and progression-free survival than patients who did not.

Panelists at Patient-Centered Oncology Care® 2020 discussed practical methods and the potential benefits of utilizing chronic care management (CCM) billing and telehealth in oncology.

Pharmacy benefit managers (PBMs), once just administrators created to ease claims processing, have grown to a position of power that comes with conflicts of interest aplenty, said a panel at Patient-Centered Oncology Care® 2020.

Neeraj Agarwal, MD, a clinician and researcher at the University of Utah Huntsman Cancer Institute, discusses investigational combinations with PARP inhibitors in prostate cancer treatment.

Kashyap Patel, MD, associate editor of Evidence-Based Oncology, a publication of The American Journal of Managed Care, will serve a 1-year term beginning in January.

Women had higher survival rates after lung cancer compared with men, regardless of other risk factors, in a population-based registry study from the Karolinska Instituet in Sweden.

A combination of pembrolizumab with bevacizumab and cyclophosphamide showed clinical activity and tolerability in patients with recurrent ovarian cancer, a small study found.

Neeraj Agarwal, MD, of the University of Utah's Huntsman Cancer Institute, discusses ongoing trials of PARP inhibitors as first-line metastatic prostate cancer treatments.

Gregory Vidal, MD, PhD, West Cancer Center and Research Institute, discusses the methodology of the Neat-HER study on neratinib in the extended adjuvant setting in HER2-positive breast cancer.

A spotlight poster discussion at SABCS highlighted topics in genomic testing, potentially game-changing therapies, and predictive biomarkers in HR-positive breast cancer.

Poster presentations at the San Antonio Breast Cancer Symposium demonstrated the clinical relevance and efficacy of oral paclitaxel plus encequidar in the treatment of metastatic breast cancer.

Yuan Yuan, MD, PhD, medical oncologist at City of Hope, discusses an ongoing study on ipatasertib with chemotherapy and atezolizumab presented at the San Antonio Breast Cancer Symposium 2020.